Fortis Healthcare Limited has announced the approval of its unaudited standalone and consolidated financial results for the quarter ended September 30, 2025. The board’s decision, made on November 11, 2025, reflects a comprehensive review by the Audit Committee. Key highlights include a consolidated revenue from operations of ₹233.14 crore and a net profit of ₹32.88 crore, indicating a steady performance despite ongoing investigations and market challenges.
Financial Performance Highlights
Fortis Healthcare Limited reported a consolidated revenue from operations of ₹233.14 crore for the quarter ended September 30, 2025. The company’s net profit for the same period stood at ₹32.88 crore. This performance was reviewed and approved by the Board of Directors on November 11, 2025, following a detailed assessment by the Audit Committee.
Segmental Performance
The group’s healthcare segment recorded revenue of ₹197.38 crore, while the diagnostics segment contributed ₹39.96 crore. The total segment profit before interest and tax was ₹45.05 crore, with healthcare accounting for ₹37.57 crore and diagnostics for ₹7.48 crore.
Key Financial Metrics
Key financial metrics for the quarter include:
- Earnings per share: ₹4.26
- Earnings before depreciation, interest, and tax (EBITDA): ₹57.89 crore
Ongoing Investigations and Legal Matters
The announcement acknowledges ongoing investigations by the Serious Fraud Investigation Office (SFIO) regarding alleged improper transactions. Fortis continues to cooperate with regulatory bodies, providing necessary information and addressing related concerns. The company has also initiated civil recovery actions to reclaim unutilized CSR funds.
Additional Key Updates
Additional updates from the announcement include:
- The board approved the execution of a Business Transfer Agreement (BTA) for the Richmond Road Hospital, resulting in a gain of ₹2,350 lacs.
- Entry into an operation and maintenance service agreement with Gleneagles Healthcare India Private Limited.
Regulatory Updates
There are multiple ongoing regulatory matters, and legal proceedings, involving the company and its subsidiaries. These include appeals before the Securities Appellate Tribunal, actions against erstwhile promoters, and various proceedings before the Delhi High Court and other regulatory bodies. Fortis is actively engaged in addressing these legal and regulatory issues while maintaining its operational efficiency.
Source: BSE
